Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment

Basit Öğe Kaydı
dc.contributor.authorGunes, Mehmet
dc.contributor.authorCamkurt, Mehmet Akif
dc.contributor.authorBulut, Mahmut
dc.contributor.authorDemir, Suleyman
dc.contributor.authorIbiloglu, Aslihan Okan
dc.contributor.authorKaya, Mehmet Cemal
dc.contributor.authorAtli, Abdullah
dc.date.accessioned2024-04-24T17:33:09Z
dc.date.available2024-04-24T17:33:09Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who, are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls, Methods: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti psychotics) and 43 healthy controls. Results: MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005): PON1 activity was similar in all groups. Conclusion: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.en_US
dc.identifier.doi10.9758/cpn.2016.14.4.345
dc.identifier.endpage350en_US
dc.identifier.issn1738-1088
dc.identifier.issn2093-4327
dc.identifier.issue4en_US
dc.identifier.pmid27776386
dc.identifier.scopus2-s2.0-84992513855
dc.identifier.scopusqualityQ2
dc.identifier.startpage345en_US
dc.identifier.urihttps://doi.org/10.9758/cpn.2016.14.4.345
dc.identifier.urihttps://hdl.handle.net/11468/20474
dc.identifier.volume14en_US
dc.identifier.wosWOS:000387300400004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKorean Coll Neuropsychopharmacologyen_US
dc.relation.ispartofClinical Psychopharmacology and Neuroscience
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectParaoxonaseen_US
dc.subjectArylesteraseen_US
dc.subjectMalondialdehydeen_US
dc.subjectSchizophreniaen_US
dc.subjectAntipsychoticsen_US
dc.subjectTreatmenten_US
dc.titleEvaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatmenten_US
dc.titleEvaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu